266 related articles for article (PubMed ID: 23600457)
21. Homozygous mutation of the LRRK2 ROC domain as a novel genetic model of parkinsonism.
Chen ML; Wu RM
J Biomed Sci; 2022 Aug; 29(1):60. PubMed ID: 35965315
[TBL] [Abstract][Full Text] [Related]
22. [Clinical features of LRRK2-associated Parkinson's disease].
Pchelina SN; Ivanova ON; Emel'ianov AK; Iakimovskiĭ AF
Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(12):56-62. PubMed ID: 22433811
[TBL] [Abstract][Full Text] [Related]
23. Prevalence and clinical features of LRRK2 mutations in patients with Parkinson's disease in southern Spain.
Gao L; Gómez-Garre P; Díaz-Corrales FJ; Carrillo F; Carballo M; Palomino A; Díaz-Martín J; Mejías R; Vime PJ; López-Barneo J; Mir P
Eur J Neurol; 2009 Aug; 16(8):957-60. PubMed ID: 19473361
[TBL] [Abstract][Full Text] [Related]
24. Low frequency of common LRRK2 mutations in Mexican patients with Parkinson's disease.
Yescas P; López M; Monroy N; Boll MC; Rodríguez-Violante M; Rodríguez U; Ochoa A; Alonso ME
Neurosci Lett; 2010 Nov; 485(2):79-82. PubMed ID: 20727385
[TBL] [Abstract][Full Text] [Related]
25. (R1441C) LRRK2 induces the degeneration of SN dopaminergic neurons and alters the expression of genes regulating neuronal survival in a transgenic mouse model.
Weng YH; Chen CY; Lin KJ; Chen YL; Yeh TH; Hsiao IT; Chen IJ; Lu CS; Wang HL
Exp Neurol; 2016 Jan; 275 Pt 1():104-15. PubMed ID: 26363496
[TBL] [Abstract][Full Text] [Related]
26. Mutations in LRRK2 impair NF-κB pathway in iPSC-derived neurons.
López de Maturana R; Lang V; Zubiarrain A; Sousa A; Vázquez N; Gorostidi A; Águila J; López de Munain A; Rodríguez M; Sánchez-Pernaute R
J Neuroinflammation; 2016 Nov; 13(1):295. PubMed ID: 27863501
[TBL] [Abstract][Full Text] [Related]
27. The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson's disease.
Zuo L; Motherwell MS
Gene; 2013 Dec; 532(1):18-23. PubMed ID: 23954870
[TBL] [Abstract][Full Text] [Related]
28. Leucine-rich repeat kinase 2 disturbs mitochondrial dynamics via Dynamin-like protein.
Niu J; Yu M; Wang C; Xu Z
J Neurochem; 2012 Aug; 122(3):650-8. PubMed ID: 22639965
[TBL] [Abstract][Full Text] [Related]
29. Olfactory deficits and cardiac 123I-MIBG in Parkinson's disease related to the LRRK2 R1441G and G2019S mutations.
Ruiz-Martínez J; Gorostidi A; Goyenechea E; Alzualde A; Poza JJ; Rodríguez F; Bergareche A; Moreno F; López de Munain A; Martí Massó JF
Mov Disord; 2011 Sep; 26(11):2026-31. PubMed ID: 21611983
[TBL] [Abstract][Full Text] [Related]
30. Penetrance in Parkinson's disease related to the LRRK2 R1441G mutation in the Basque country (Spain).
Ruiz-Martínez J; Gorostidi A; Ibañez B; Alzualde A; Otaegui D; Moreno F; López de Munain A; Bergareche A; Gómez-Esteban JC; Martí Massó JF
Mov Disord; 2010 Oct; 25(14):2340-5. PubMed ID: 20721916
[TBL] [Abstract][Full Text] [Related]
31. LRRK2 enhances oxidative stress-induced neurotoxicity via its kinase activity.
Heo HY; Park JM; Kim CH; Han BS; Kim KS; Seol W
Exp Cell Res; 2010 Feb; 316(4):649-56. PubMed ID: 19769964
[TBL] [Abstract][Full Text] [Related]
32. A novel mitochondrially-targeted apocynin derivative prevents hyposmia and loss of motor function in the leucine-rich repeat kinase 2 (LRRK2(R1441G)) transgenic mouse model of Parkinson's disease.
Dranka BP; Gifford A; McAllister D; Zielonka J; Joseph J; O'Hara CL; Stucky CL; Kanthasamy AG; Kalyanaraman B
Neurosci Lett; 2014 Nov; 583():159-64. PubMed ID: 25263790
[TBL] [Abstract][Full Text] [Related]
33.
Kim J; Daadi EW; Daadi ES; Oh T; Deleidi M; Daadi MM
Cells; 2023 Oct; 12(21):. PubMed ID: 37947628
[TBL] [Abstract][Full Text] [Related]
34. Apoptotic mechanisms in mutant LRRK2-mediated cell death.
Iaccarino C; Crosio C; Vitale C; Sanna G; Carrì MT; Barone P
Hum Mol Genet; 2007 Jun; 16(11):1319-26. PubMed ID: 17409193
[TBL] [Abstract][Full Text] [Related]
35. Changes in matrix metalloprotease activity and progranulin levels may contribute to the pathophysiological function of mutant leucine-rich repeat kinase 2.
Caesar M; Felk S; Zach S; Brønstad G; Aasly JO; Gasser T; Gillardon F
Glia; 2014 Jul; 62(7):1075-92. PubMed ID: 24652679
[TBL] [Abstract][Full Text] [Related]
36. Identification of a Japanese family with LRRK2 p.R1441G-related Parkinson's disease.
Hatano T; Funayama M; Kubo SI; Mata IF; Oji Y; Mori A; Zabetian CP; Waldherr SM; Yoshino H; Oyama G; Shimo Y; Fujimoto KI; Oshima H; Kunii Y; Yabe H; Mizuno Y; Hattori N
Neurobiol Aging; 2014 Nov; 35(11):2656.e17-2656.e23. PubMed ID: 24973808
[TBL] [Abstract][Full Text] [Related]
37. Lrrk2 mutations in South America: A study of Chilean Parkinson's disease.
Perez-Pastene C; Cobb SA; Díaz-Grez F; Hulihan MM; Miranda M; Venegas P; Godoy OT; Kachergus JM; Ross OA; Layson L; Farrer MJ; Segura-Aguilar J
Neurosci Lett; 2007 Jul; 422(3):193-7. PubMed ID: 17614198
[TBL] [Abstract][Full Text] [Related]
38. Mutations in LRRK2 as a cause of Parkinson's disease.
Giasson BI; Van Deerlin VM
Neurosignals; 2008; 16(1):99-105. PubMed ID: 18097165
[TBL] [Abstract][Full Text] [Related]
39. Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease.
Büeler H
Exp Neurol; 2009 Aug; 218(2):235-46. PubMed ID: 19303005
[TBL] [Abstract][Full Text] [Related]
40. Neuroprotective Effect of the LRRK2 Kinase Inhibitor PF-06447475 in Human Nerve-Like Differentiated Cells Exposed to Oxidative Stress Stimuli: Implications for Parkinson's Disease.
Mendivil-Perez M; Velez-Pardo C; Jimenez-Del-Rio M
Neurochem Res; 2016 Oct; 41(10):2675-2692. PubMed ID: 27394417
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
